Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer (SYSUCC-001)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01112826|
Recruitment Status : Completed
First Posted : April 28, 2010
Last Update Posted : May 27, 2020
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Capecitabine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||443 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast Cancer|
|Actual Study Start Date :||April 23, 2010|
|Actual Primary Completion Date :||December 31, 2019|
|Actual Study Completion Date :||December 31, 2019|
Capecitabine 650 mg/m2 bid
capecitabine 650 mg/m2 twice every day for 1 year.
No Intervention: Standard treatment
Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
- disease-free survival [ Time Frame: 36 months ]The final analysis are expected to occur 36 months after the end of recruitment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01112826
|Sun Yat-sen University, Cancer Center|
|Guangzhou, Guangdong, China, 510060|
|Study Director:||Yuan Zhong-yu, MD||Sun Yat-sen University|